Tags

Type your tag names separated by a space and hit enter

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
Dement Geriatr Cogn Disord 2007; 24(1):20-7DG

Abstract

The efficacy of memantine in Alzheimer's disease (AD) has been investigated in multiple randomised, placebo-controlled phase III trials. Recently, the indication label for memantine in Europe was extended to cover patients with moderate to severe AD, i.e. Mini-Mental State Exam total scores below 20. The efficacy data for memantine in this patient subgroup has been summarised by a meta-analysis of 1,826 patients in six trials. Efficacy was assessed using measures of global status (Clinician's Interview-Based Impression of Change Plus Caregiver Input), cognition (Alzheimer's Disease Assessment Scale - Cognitive Subscale, or Severe Impairment Battery), function (Alzheimer's Disease Cooperative Study Activities of Daily Living 19- or 23-item scale), and behaviour (Neuropsychiatric Inventory). Results (without replacement of missing values) showed statistically significant effects for memantine (vs. placebo) in each domain. Memantine was well tolerated, and the overall incidence rates of adverse events were comparable to placebo. This meta-analysis supports memantine's clinically relevant efficacy in patients with moderate to severe AD.

Authors+Show Affiliations

Karolinska Institutet, Stockholm, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17496417

Citation

Winblad, Bengt, et al. "Memantine in Moderate to Severe Alzheimer's Disease: a Meta-analysis of Randomised Clinical Trials." Dementia and Geriatric Cognitive Disorders, vol. 24, no. 1, 2007, pp. 20-7.
Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20-7.
Winblad, B., Jones, R. W., Wirth, Y., Stöffler, A., & Möbius, H. J. (2007). Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders, 24(1), pp. 20-7.
Winblad B, et al. Memantine in Moderate to Severe Alzheimer's Disease: a Meta-analysis of Randomised Clinical Trials. Dement Geriatr Cogn Disord. 2007;24(1):20-7. PubMed PMID: 17496417.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. AU - Winblad,Bengt, AU - Jones,Roy W, AU - Wirth,Yvonne, AU - Stöffler,Albrecht, AU - Möbius,Hans Jörg, Y1 - 2007/05/10/ PY - 2007/03/06/accepted PY - 2007/5/15/pubmed PY - 2007/10/2/medline PY - 2007/5/15/entrez SP - 20 EP - 7 JF - Dementia and geriatric cognitive disorders JO - Dement Geriatr Cogn Disord VL - 24 IS - 1 N2 - The efficacy of memantine in Alzheimer's disease (AD) has been investigated in multiple randomised, placebo-controlled phase III trials. Recently, the indication label for memantine in Europe was extended to cover patients with moderate to severe AD, i.e. Mini-Mental State Exam total scores below 20. The efficacy data for memantine in this patient subgroup has been summarised by a meta-analysis of 1,826 patients in six trials. Efficacy was assessed using measures of global status (Clinician's Interview-Based Impression of Change Plus Caregiver Input), cognition (Alzheimer's Disease Assessment Scale - Cognitive Subscale, or Severe Impairment Battery), function (Alzheimer's Disease Cooperative Study Activities of Daily Living 19- or 23-item scale), and behaviour (Neuropsychiatric Inventory). Results (without replacement of missing values) showed statistically significant effects for memantine (vs. placebo) in each domain. Memantine was well tolerated, and the overall incidence rates of adverse events were comparable to placebo. This meta-analysis supports memantine's clinically relevant efficacy in patients with moderate to severe AD. SN - 1420-8008 UR - https://www.unboundmedicine.com/medline/citation/17496417/Memantine_in_moderate_to_severe_Alzheimer's_disease:_a_meta_analysis_of_randomised_clinical_trials_ L2 - https://www.karger.com?DOI=10.1159/000102568 DB - PRIME DP - Unbound Medicine ER -